Effects of Crocin in Treatment of Diabetes

The effects of Crocin supplementation on metabolic parameters, systemic inflammation and AMP- activated protein kinase, TNF-a and NF-Kß in patients with type 2 diabetes.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170408033308N2

Enrollment

Registered

2019-08-13

Start date

2019-02-18

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: Crocin supplementation: they will receive, for 12 weeks, two tablets of Crocina (Samisaz Company) per day, each containing 15 mg of crocin. Intervention 2: Control

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Aged 30-70 years old Clinical diagnosis of type 2 diabetes (for at least 1 year) Body mass index (BMI) 18.5-30 kg/m2

Exclusion criteria

Exclusion criteria: Having liver, kidney, inflammatory and pulmonary diseases; Alcohol-drug abuse; Pregnancy and lactation; Insulin injection.

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzymatic assay kit.;Serum concentrations of insulin. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Hemoglobin A1C levels. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzymatic assay kit.;Serum concentrations of malondialdehyde (MDA). Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Concentrations of nuclear factor kappa-? in peripheral blood mononuclear cells. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of high sensitivity c-reactive protein (hs-CRP). Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentration of Interleukin 6. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Concentrations of tumor necrosis factor alpha in peripheral blood mononuclear cells. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Concentrations of AMP-activated protein kinase in peripheral blood mononuclear cells. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum concentrations of triglyceride. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzymatic assay kit.;Serum concentrations of total cholesterol. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement:	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzymatic assay kit.;Serum concentrations of insulin. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Hemoglobin A1C levels. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzymatic assay kit.;Serum concentrations of malondialdehyde (MDA). Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Concentrations of nuclear factor kappa-? in peripheral blood mononuclear cells. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of high sensitivity c-reactive protein (hs-CRP). Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentration of Interleukin 6. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Concentrations of tumor necrosis factor alpha in peripheral blood mononuclear cells. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Concentrations of AMP-activated protein kinase in peripheral blood mononuclear cells. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kit.;Serum concentrations of triglyceride. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: Enzymatic assay kit.;Serum concentrations of total cholesterol. Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement:

—

Secondary

Measure	Time frame
Serum concentration of Total oxidant capacity (TOC). Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentration of Total anti-oxidant capacity (TAC). Timepoint: Before the intervention and 12 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahideh Behrouz

Shahid Beheshti University of Medical Sciences

Vahideh.behrouz@gmail.com+98 21 2207 7424

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026